TY - JOUR
T1 - Resection of primary tumor at diagnosis in stage IV-S neuroblastoma
T2 - Does it affect the clinical course?
AU - Guglielmi, M.
AU - De Bernardi, B.
AU - Rizzo, A.
AU - Federici, S.
AU - Boglino, C.
AU - Siracusa, F.
AU - Leggio, A.
AU - Cozzi, F.
AU - Cecchetto, G.
AU - Musi, L.
AU - Bardini, T.
AU - Fagnani, A. M.
AU - Bartoli, G. C.
AU - Pampaloni, A.
AU - Rogers, D.
AU - Conte, M.
AU - Milanaccio, C.
AU - Bruzzi, P.
PY - 1996/5
Y1 - 1996/5
N2 - Purpose: To determine whether resection of primary tumor has a favorable influence on outcome of infants (age 0 to 11 months) with stage IV-S neuroblastoma. Patients and Methods: Between March 1976 and December 1993, 97 infants with previously untreated neuroblastoma diagnosed in 21 Italian institutions were classified as having stage IV-S disease. Seventy percent were younger than 4 months. Adrenal was the primary tumor site in 64 of 85 patients with a recognizable primary tumor. Liver was the organ most often infiltrated by the tumor (82 patients), followed by bone marrow and skin. Results: The overall survival (OS) rate at 5 years is 80% and event-free survival (EFS) rate 68%. In 24 infants, the effect of resection of primary tumor could not be evaluated because of rapidly fatal disease progression (n = 8), absence of a primary tumor (n = 12), or partial resection (n = 4). Of 73 assessable patients, 26 underwent primary tumor resection at diagnosis: one died of surgical complications, one relapsed locally and died, and two others relapsed (one of these two locally) and survived, far a 5-year OS rate of 92% and EFS rate of 84%. Of the remaining 47 patients who did not undergo primary tumor resection at diagnosis 11 suffered unfavorable events, of whom five died, for an OS rate of 89% and EFS rate of 75% (no significant difference from previous group). Disease recurred at the primary tumor site in only one of five who died, and in only one of six survivors of progression or relapse; in these patients, the primary tumor, located in the mediastinum, was successfully resected. Conclusion: Infants who underwent resection of the primary tumor at diagnosis had no better outcome than those in whom the decision was made not to operate.
AB - Purpose: To determine whether resection of primary tumor has a favorable influence on outcome of infants (age 0 to 11 months) with stage IV-S neuroblastoma. Patients and Methods: Between March 1976 and December 1993, 97 infants with previously untreated neuroblastoma diagnosed in 21 Italian institutions were classified as having stage IV-S disease. Seventy percent were younger than 4 months. Adrenal was the primary tumor site in 64 of 85 patients with a recognizable primary tumor. Liver was the organ most often infiltrated by the tumor (82 patients), followed by bone marrow and skin. Results: The overall survival (OS) rate at 5 years is 80% and event-free survival (EFS) rate 68%. In 24 infants, the effect of resection of primary tumor could not be evaluated because of rapidly fatal disease progression (n = 8), absence of a primary tumor (n = 12), or partial resection (n = 4). Of 73 assessable patients, 26 underwent primary tumor resection at diagnosis: one died of surgical complications, one relapsed locally and died, and two others relapsed (one of these two locally) and survived, far a 5-year OS rate of 92% and EFS rate of 84%. Of the remaining 47 patients who did not undergo primary tumor resection at diagnosis 11 suffered unfavorable events, of whom five died, for an OS rate of 89% and EFS rate of 75% (no significant difference from previous group). Disease recurred at the primary tumor site in only one of five who died, and in only one of six survivors of progression or relapse; in these patients, the primary tumor, located in the mediastinum, was successfully resected. Conclusion: Infants who underwent resection of the primary tumor at diagnosis had no better outcome than those in whom the decision was made not to operate.
UR - http://www.scopus.com/inward/record.url?scp=9244255813&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9244255813&partnerID=8YFLogxK
M3 - Article
C2 - 8622069
AN - SCOPUS:9244255813
VL - 14
SP - 1537
EP - 1544
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 5
ER -